C.2 SUNFISH parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)

MLA

Mah, Jk, et al. “C.2 SUNFISH Parts 1 and 2: 4-Year Efficacy and Safety Data of Risdiplam in Types 2 and 3 Spinal Muscular Atrophy (SMA).” The Canadian Journal of Neurological Sciences, vol. 50, no. Supplement 2, June 2023, pp. S51–52. EBSCOhost, https://doi.org/10.1017/cjn.2023.88.

APA

Mah, J., Oskoui, M., Day, J., Deconinck, N., Mazzone, E., Nascimento, A., Saito, K., Vuillerot, C., Baranello, G., Boespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Braid, J., Gerber, M., Gorni, K., Martin, C., Yeung, W., … Mercuri, E. (2023). C.2 SUNFISH parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). The Canadian Journal of Neurological Sciences, 50(Supplement 2), S51–S52. https://doi.org/10.1017/cjn.2023.88

Chicago

Mah, Jk, M Oskoui, Jw Day, N Deconinck, E Mazzone, A Nascimento, K Saito, et al. 2023. “C.2 SUNFISH Parts 1 and 2: 4-Year Efficacy and Safety Data of Risdiplam in Types 2 and 3 Spinal Muscular Atrophy (SMA).” The Canadian Journal of Neurological Sciences 50 (Supplement 2): S51–52. doi:10.1017/cjn.2023.88.